NEW YORK – Biotech Immunome has given the first patient with a solid tumor its fibroblast activation protein (FAP)-targeted radioligand therapy within a clinical trial, the company announced Monday.
If approved after priority review, the firm anticipates launching DYNE-251 in the US in the first quarter of next year.
After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...
The anti-amyloid drug is designed for a limited course, where patients can stop treatment once they reach a level of ...
Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...
The focus on treating people who have no cognitive impairment raises questions about how to implement testing for those at ...
NEW YORK – The US Food and Drug Administration has cleared Umoja Biopharma to begin a Phase I/II trial for its CD22-directed in vivo CAR T-cell therapy, UB-VV400, in patients with relapsed or ...
A panel determined that Tafinlar and Adcetris will be offered to certain patients but passed on several other precision therapies.
Primary care docs in Sweden diagnosed Alzheimer's with the same accuracy as dementia specialists when they had access to beta ...
The therapy was first granted accelerated approval for solid tumors in 2022 based on the ongoing LIBRETTO-001 trial in adults and another pediatric trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results